Lian LY, Huang CX, Chen QF, Zhou XD. Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution. World J Cardiol 2025; 17(2): 103845 [DOI: 10.4330/wjc.v17.i2.103845]
Corresponding Author of This Article
Xiao-Dong Zhou, MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou 325000, Zhejiang Province, China. zhouxiaodong@wmu.edu.cn
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Li-You Lian, Chen-Xiao Huang, Xiao-Dong Zhou, MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Qin-Fen Chen, Department of Physical Examination Medical Care Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Supported by Wenzhou Science Technology Bureau Foundation, No. 2022Y0726.
Conflict-of-interest statement: Li-You Lian, Chen-Xiao Huang, Qin-Fen Chen and Xiao-Dong Zhou have nothing to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Dong Zhou, MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou 325000, Zhejiang Province, China. zhouxiaodong@wmu.edu.cn
Received: December 3, 2024 Revised: January 16, 2025 Accepted: January 21, 2025 Published online: February 26, 2025 Processing time: 84 Days and 20.7 Hours
Abstract
Heart failure (HF) with preserved ejection fraction (HFpEF) has exceeded HF with reduced ejection fraction (HFrEF), becoming the most common type of HF. Unlike HFrEF, HFpEF is primarily a chronic low-grade inflammatory process closely associated with metabolic disorders. The coexistence of HFpEF and metabolic dysfunction-associated steatotic liver disease (MASLD) presents significant clinical challenges due to shared metabolic pathophysiology and complex interplay. Management strategies for HFpEF and MASLD remain challenging. Sodium-glucose cotransporter 2 inhibitors have shown benefits in managing both conditions. Additionally, glucagon-like peptide-1 receptor agonists are being actively investigated for their potential benefits, particularly in MASLD. A comprehensive, patient-centered approach that combines metabolic and cardiovascular care is essential for improving outcomes in patients with HFpEF and MASLD, addressing the global metabolic health challenges.
Core Tip: The coexistence of heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatotic liver disease (MASLD), poses significant clinical challenges due to their intricate relationship and similar metabolic pathophysiology. Clinical management strategies for HFpEF and MASLD still faces challenges. Sodium-glucose cotransporter 2 inhibitors showing benefits in HFpEF or MASLD, while other drugs, such as glucagon-like peptide-1 receptor agonists and statins remains under investigation. A holistic, patient-centered approach combining metabolic and cardiovascular care is vital for improving HFpEF and MASLD outcomes in global metabolic health challenges.
